Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

l. One subject did not complete the trial due to personal reasons and one other subject did not complete the trial due to a serious adverse event, cholecystitis (gall stones), which was judged not related to the study drug.

Based on these important findings, the Company now plans to adjust its future dosing. Expanded Phase 2 planning is moving forward to include Phase 2 IVUS trials, a Phase 2 dosing trial and a Phase 2 combination statin trial. The IVUS Steering Committee is chaired by Dr. Steven Nissen, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine, and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland Clinic.

"The results we have observed in our second clinical trial illustrate an important emerging pattern of predictability. To date 162 human subjects have received RVX-208 which has consistently demonstrated itself to be a well tolerated and safe therapeutic," stated Dr. Jan Johansson Senior Vice President of Medical Affairs at Resverlogix. "It is important to note that in addition to the increases in ApoA-I and HDL, we also saw very pronounced increases in alpha-1 HDL, another important marker for CVD risk. The landmark Framingham Offspring Study clearly illustrated that among HDL and LDL, alpha-1 HDL was a more critically important marker for CVD protection," Dr. Johansson added.

Developing small molecules that increase ApoA-I would satisfy a huge unmet medical need because CVD treatment with statins, the current standard of care, only stabilizes atherosclerosis and reduces cardiovascular risk by 30%. A recent cost-benefit pharmacoeconomic analysis of ApoA-I therapy for CVD estimated that a 1% and 5% regression of atherosclerosis would save the U.S. health care system and employers between US $22.9 billion and US $76.8 billion annually over and above statin therapy. The analysis assumes ApoA-I therapy will be
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... 21, 2011 United Therapeutics Corporation (Nasdaq: ... its FREEDOM-C(2) registration trial was completed on March ... multi-center, international, double-blind, randomized, placebo-controlled study of a ... in pulmonary arterial hypertension (PAH) patients receiving an ...
... Paul Braun,s lab look like any others, but they ... three-dimensional nanostructure for battery cathodes that allows for dramatically ... The researchers, findings will be published in the March ... Nanotechnology. Aside from quick-charge consumer electronics, batteries ...
... 18, 2011 Driving value for customers is critical to ... points between a customer and an organization, there has to ... an organization to succeed in the marketplace. ... Practices, LLC., noted in this month,s special issue of PharmaVoice ...
Cached Biology Technology:United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Batteries charge quickly and retain capacity, thanks to new structure 2Batteries charge quickly and retain capacity, thanks to new structure 3Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... July 14, 2009 NYU and NYU School of ... Award from the National Institutes of Health (NIH) to establish ... with the New York City Health and Hospitals Corporation (HHC). ... rapidly advance science from the lab to the patient to ...
... French cave of Arago, an international team of scientists has analyzed ... Homo heidelbergensis . It is the first time that an ... occupations at archaeological sites. The key is the last food that ... of the groups of hominids and how long they spent in ...
... Nanyang Technological University (NTU),s Assistant Professor Li Hoi Yeung, ... made an important contribution to the understanding of the ... process known as ,apoptosis, or programmed cell death, is ... perhaps a million cells a second. According to ...
Cached Biology News:$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 2$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 3$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 4The last supper of the hominids establishes the times they lived at the sites 2Study by NTU professors provides important insight into apoptosis or programmed cell death 2
... platform for fully automated systems for a ... be configured for applications ranging from compound ... closed loop screening, which means it has ... cherry picking and follow up studies all ...
... are disposable microfiltration devices for the fast and ... 100 l to 500 l. They can be ... centrifuge tubes. Product Features: High-flux Polyethersulphonemembrane ... Low hold up volume ( Fast and reproducible ...
... Caliper Prelude Workstation fully automates pharmaceutical ... addition, extraction, sample transfer, mixing and ... and UV detection. The Prelude performs ... 21 CFR Part 11. The ...
... any standard fixed-angle microcentrifuge rotor at ... centrifuge tube filters consist of a ... tube. They filter by centrifugation for ... preparation, removal of cells from media ...
Biology Products: